Aldeyra Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aldeyra Therapeutics, Inc. on September 13, 2016. The report discloses corporate governance changes, specifically the election of a new director and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on board composition and director compensation.
Material Changes
- Board Expansion: The Board of Directors increased the total number of directors to eight.
- New Director Election: Richard H. Douglas, Ph.D., was elected as a Class II director. His initial term expires at the 2019 annual meeting of stockholders.
- Independence: The Board determined that Dr. Douglas is an independent director in accordance with SEC and Nasdaq rules.
Compensatory Arrangements and Governance
In connection with his election, Dr. Douglas received the following compensation under the Company's non-employee director program:
- Initial Stock Option: Granted 12,166 shares of common stock with an exercise price equal to the closing stock price on September 13, 2016. This option vests ratably in annual installments over three years.
- Annual Cash Fee: An annual fee of $17,500 for service as a director.
- Annual Stock Option: Eligible to receive an option to purchase 6,083 shares upon the conclusion of each annual meeting of stockholders. These options vest in full on the one-year anniversary of the grant date.
- Indemnification: Dr. Douglas entered into an indemnification agreement requiring the Company to indemnify him to the fullest extent permitted under Delaware law.
Investor Verification Checklist
- Verify the independence status of Dr. Douglas as disclosed in the filing.
- Review the attached Press Release (Exhibit 99.1) for additional context on the appointment.
- Confirm the vesting schedule and exercise price of the initial 12,166 share option grant.
- Check the Company's Proxy Statement for the 2016 Annual Meeting for full details on the non-employee director compensation program.